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Abstract. Pathologist-defined labels are the gold standard for histopatho-
logical data sets, regardless of well-known limitations in consistency for
some tasks. To date, some datasets on mitotic figures are available and
were used for development of promising deep learning-based algorithms.
In order to assess robustness of those algorithms and reproducibility of
their methods it is necessary to test on several independent datasets.
The influence of different labeling methods of these available datasets is
currently unknown. To tackle this, we present an alternative set of labels
for the images of the auxiliary mitosis dataset of the TUPAC16 chal-
lenge. Additional to manual mitotic figure screening, we used a novel,
algorithm-aided labeling process, that allowed to minimize the risk of
missing rare mitotic figures in the images. All potential mitotic figures
were independently assessed by two pathologists. The novel, publicly
available set of labels contains 1,999 mitotic figures (+28.80%) and ad-
ditionally includes 10,483 labels of cells with high similarities to mitotic
figures (hard examples). We found significant difference comparing F1
scores between the original label set (0.549) and the new alternative
label set (0.735) using a standard deep learning object detection archi-
tecture. The models trained on the alternative set showed higher overall
confidence values, suggesting a higher overall label consistency. Findings
of the present study show that pathologists-defined labels may vary sig-
nificantly resulting in notable difference in the model performance. Com-
parison of deep learning-based algorithms between independent datasets
with different labeling methods should be done with caution.
Keywords: breast cancer, mitotic figures, computer-aided annotation,
deep learning
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1 Introduction
Deep learning-based methods have shown to be powerful in the development of
automated image analysis software in digital pathology. This innovative field of
research has been fostered by creation of publicly available data sets of specific
histological structures. One of the most extensively researched cell structures in
current literature are mitotic figures (microscopic appearance of a cell under-
going cell division) in neoplastic tissue. Quantification of the highest density of
mitotic figures is one of the most important histological criteria for assessment
of biological tumor behavior and this pattern has therefore drawn much research
attention for computerized methods.
Manual enumeration of mitotic figures by pathology experts has some lim-
itations including high inter-rater inconsistency of pathologists in classifying
individual cells as mitotic figures as they exhibit a high degree of morphological
variability and similarity to some non-mitotic structures. In previous studies,
disagreement of classification occurred in 6.4-35.3% [8], and 68.2% [13] of labels.
This calls for algorithm-assisted approaches in order to increase reproducibil-
ity as it has been proven that algorithms can have substantial agreement with
pathologists on the object level [15]. Poor consistency of expert classification is,
however, also a potential bias for deep learning-based methods, as pathologists
are the current gold standard for assessment of morphological patterns, including
mitotic figures, and creation of histological ground truth datasets. Due to the
high inter-observer discordance of pathologists, we suspect some variability in
assigned labels if images are annotated a second time. The usage of pathologist-
defined labels for machine learning methods are thus somewhat a paradox as
algorithmic methods, which are trained with and tested on these partially noisy
ground truths, aim to overcome cognitive and visual limitations of pathologists.
In order to assess the robustness of algorithms and the reproducibility of
newly developed deep learning-based methods it is necessary to test on several
independent ground truth datasets. For these aspects, images should be indepen-
dent but the ground truth should ideally be consistent throughout the datasets.
To date, several open access datasets are available with labels for mitotic figures
in digitalized microscopy images of human breast cancer [10,11,14] and canine
cutaneous mast cell tumors [5], which have been developed by three research
groups with somewhat variable labeling methods. As several publications have
compared their algorithmic approaches between these publicly available datasets
(for example [4,1,6]), a strong difference in test performance is known for these
datasets. However, the influence of variability in the ground truth labels on train-
ing and test performance is currently unknown. In the present work, we have
developed an alternative ground truth dataset for one of those publicly available
images sets and assessed the difference to the original dataset. This was done
using a new labeling methodology, targeted towards improved identification of
mitotic figure events, and supported by the use of deep learning.
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2 Related Work
Most publicly available data sets with annotations for mitotic figures are from
human breast cancer, due to the high prevalence and high prognostic importance
of the mitotic count for this tumor type. Roux et al. were the first to present a
data set, consisting of five cases scanned by two whole slide scanners (and one
multi-spectral scanner) and annotated by a single pathologist (ICPR MITOS
2012, [11]). The biggest limitation of this dataset was the potential overlap of
training and test images, which were retrieved from different locations of the
same whole slide images (WSI). A year later, the MICCAI AMIDA 13 challenge
introduced a new data set, covering in total 23 cases, which were evenly spread
between training and test set [13]. They were the first to acknowledge potential
bias (inter-rater variance) by a single pathologist and thus perform the task by
two pathologists independently, with a panel of two additional pathologists judg-
ing discordant annotations (see Fig. 1). The following year, the group behind the
MITOS 2012 data set introduced an extended data set at ICPR (ICPR MITOS
2014, [10]), consisting of 16 cases (11 for training and 5 for test), again scanned
using two scanners, but this time including annotations from two pathologists.
In case the pathologists disagreed, a third pathologist decided for the particular
cell. The data sets includes also an expert confidence score for each mitotic figure
as well as for cells probably not mitotic figures (hard negative cells). The most
recent mitotic figure dataset was part of the TUPAC16 challenge [14], incorpo-
rating all 23 AMIDA13 cases in the training set in addition to 50 new training
cases and 23 new test cases. This dataset comprises the currently the highest
number of mitotic figure labels in human breast cancer.
Data about the agreement of experts in the MITOS 2014 data set can be
extracted from the labels given by the challenge. Out of all 1,014 cells that
were flagged by at least one pathologist as mitosis or probably mitosis, only
317 (31.26%) were agreed by all pathologists to be mitotic figures, but for 749
(73.87%) the expert consensus was mitosis. For the MICCAI AMIDA 13 data
set, Veta et al. reported an agreement in 649 out of 2038 (31.84%) annotated
cells by the two initial readers, and the consensus found 1157 (56.77%) to be
actual mitotic figures [13]. The fact that for both data sets the final consensus
strongly exceeds the initial agreement highlights that spotting of rare mitotic
figure events is a difficult component in the labeling process which might lead
to data set inconsistency.
For data sets, inclusion of real-life variance of stain and tissue quality is an ad-
vantage, as the data is much more representative of a realistic use case. Current
datasets on mitotic figures exhibit some differences in staining and other charac-
teristics causing a certain domain shift [4] and somewhat limiting dataset trans-
ferability / robustness. Of the aforementioned datasets, the TUPAC16 dataset
likely includes the highest variability due to inclusion of currently highest num-
ber of cases that were retrieved from three laboratories and scanned with two
different scanners [14]. The consequence of the higher variability is an increased
difficulty for the pattern recognition task of automatic mitotic figure detection,
as also reflected by lower recognition scores achieved on the data set compared
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to the other data sets. However, this variability represents a more realistic use-
case, and is highly beneficial for the development of algorithms to be used in
heterogeneous clinical environments.
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Fig. 1. Annotation workflow in the original AMIDA13/TUPAC16 data sets [13,14].
The images were independently screened by two pathologists. All agreed mitotic figures
were directly accepted as ground truth, while disagreed cases were submitted to a panel
of two additional experts.
3 Material and Methods
3.1 Development of an Alternative Set of Labels
Due to the relevance of the TUPAC16 dataset (see above), we have decided to use
these images in the present study for assessment of reproducibility of pathologist-
defined labels. Available images from the TUPAC16 test and training set (N =
107 cases [14]) were retrieved from the TUPAC challenge website. Cases from
the AMIDA13 challenge were available as several separate, but often flanking
image sections, which we stitched to single images by utilizing correlation at
the image borders, wherever possible. The alternative dataset was developed in
a similar way as published by Bertram et al. [5]: First, one pathology expert
screened all images twice (see Fig. 2) with an open source software solution with
a guided screening mode [3]. Mitotic figures (MF) and similar structures (hard
negatives, HN) were labeled. The dataset from the first screening of the training
set included 5,833 labels (2,188 MF; 3,645 HN), and from the second screeing
7,220 labels (2,218 MF; 5,002 HN).
The dataset was given to a second pathologist, who assigned a second la-
bel (MF or HN) in a blinded manner (label class obscured) supported by the
annotation software through automatic presentation of image section with un-
classifed objects. The second pathologist assigned the MF label in 2,272 cases
and the HN label in 4,978 cases. Initial agreement for the class MF was found
for 1,713 cells (61.69%), the pathologists disagreed on 1,064 cells (14.74% of all
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Fig. 2. Labeling approach used for the creation of the alternative set of labels consisting
of two steps. First, an expert screened the slides twice, and another expert performed
a blind evaluation of all cells. Second, an algorithmic pipeline was used to detect cells
potentially missed by the manual screening. For both steps, disagreed labels were re-
evaluated by both experts in order to find a common consensus.
cells). All disagreed cells were re-evaluated by both experts, and the consensus
of the manual dataset contained 1,898 MF and 5,340 HN.
Subsequently, labels from the first expert were used for an algorithmic-aided
pipeline for detection of missed objects, like described in [5]. The pipeline ex-
tracted image patches around additionally detected mitotic figure candidates,
sorted according to their model score. The algorithm-based screening addition-
ally found 5,824 objects (mitotic figure candidates), which were then extracted as
128x128 px image patches centered around the detection. Two experts assessed
(MF or HN) these patches independently and agreed on all but 142 patches. All
agreed objects were assigned to the dataset immediately and disagreed objects
were re-evaluated by joint assessment for consensus. The final augmented data
set contains 1,999 MF and 10,483 HN. Please note that all numbers are given
only for the training part of the set to not reveal information about the test set
for further usage.
3.2 Automatic Mitosis Detection Methods
We evaluated the alternative labels using a standard, state-of-the-art object
detection approach: We customized RetinaNet [7] based on a pre-trained ResNet-
18 stem with an input size of 512×512 px to have the object detection head only
attached at the 32×32 resolution of the feature pyramid network. We chose four
different sizes (scales) of bounding boxes to enable augmentation by zooming
and rotation, but only used an 1:1 aspect ratio, since the bounding boxes were
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defined to be squares. We randomly chose 10 tumor cases to be our validation
set, which was used for model selection based on the mAP metric. After model
selection, we determined the optimum detection threshold on the concatenated
training and validation set. Models were trained on both, the original TUPAC16
label set and the novel, alternative set, and evaluated on the respective test sets
using F1 as metric.
Additionally, we calculated the model scores for individual cells of the data
sets to assess model confidence. Since the test set of both label sets are not avail-
able publicly, we used a three-fold cross-validation on the training set. For this,
we disabled the threshold normally used within the non-maximum-suppression
of the model post-processing, which enabled us to derive model scores from the
classification head of the model for all cells of our data set. We matched anno-
tations in both data sets under the assumption that that all annotations within
a distance of 25 pixels refer to the same object.
The complete training set and all code that was used for the evaluation is
made available online5. We encourage other research groups to use this alterna-
tive dataset for training their algorithms and we will provide evaluation of the
performance of detection results on the test set upon a reasonable request to the
corresponding author.
4 Results
Comparing the original and the new, alternative training label sets, we find that
they agree for 1,239 MF annotations (53.59%), while the two expert groups
disagreed on 1,073 cells (46.41%). As depicted in Fig. 3, 246 of MF identified
in the original TUPAC16 label set were assigned to be hard examples in the
alternative set, while 67 were not annotated at all. The alternative set assigned
760 further cells with the label MF, that were not annotated in the original label
set.
Looking at the concatenated model scores from the cross-validation experi-
ment, we can state that the model trained on the alternative set shows an overall
higher confidence for agreed mitotic figures. In contrast, MF labels only present
in the original TUPAC16 dataset had an overall lower model score with a ten-
dency towards higher values in the models trained on the original set (median
values are 0.326 and 0.284). The group of labels newly assigned in the alterna-
tive set shows higher scores for the model trained on the alternative set (median
value of 0.503 vs. 0.266), while the group of hard negatives has a very similar
distribution with low model scores for both training label sets.
The higher model confidence for mitotic figures on the alternative dataset
in Fig. 3 coincides with a generally higher F1 score in model performance on
the test set (see Table 1). We see a small increment for using the data set using
the machine-learning-aided detections for potentially missed cells, related to a
notable increase in precision.
5 https://github.com/DeepPathology/TUPAC_alternativeLabels
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Fig. 3. Comparison of the original TUPAC16 and alternative label sets (training part
only). The two expert teams agreed upon 1,239 mitotic figures, while the new set
contains 760 additional labels for mitotic figures and 246 out 309 disagreed cells were
labeled as hard negatives. The plot shows also the concatenated model scores given by
a RetinaNet-approach trained in three-fold cross-validation on the original (blue) and
alternative (green) label set.
5 Discussion
Labeled data is the foundation for training and testing of deep learning-based
algorithms. Although a vast diversity of labeling methods have been applied for
mitotic figure dataset development [5,9,11,10,13,14], the effects of these methods
on algorithmic performance is currently not fully understood. With recent im-
provements of deep learning methods, the demand for high-quality data is also
increasing. The currently highest reported F1 score on the original TUPAC16
dataset is 0.669 [6], which is significantly higher than the value achieved by our
standard RetinaNet approach on the same labels (F1 score: 0.549). Considering
the difference between the present and the state-of-the-art results by Li et al. [6]
on the original TUPAC16 dataset, it seems likely that also the results on the
alternative datasets may be further improved by more advanced methods, which
we encourage as we have made the alternative datasets publicly available. How-
ever, instead of aiming to achieve highest possible performance, we wanted to
assess effects of using different ground truth datasets of the same images with
the same deep learning method. The major finding of the present study was that
pathologists-defined labels are not necessarily reproducible even when using an-
notation protocols that take the consensus of several experts as the ground truth,
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metric training
test
TUPAC original alternative(manual) alternative(augmented)
F1 score
TUPAC original 0.549 0.587 0.563
alternative (augmented) 0.555 0.719 0.735
precision
TUPAC original 0.540 0.682 0.699
alternative (augmented) 0.477 0.713 0.772
recall
TUPAC original 0.559 0.515 0.471
alternative (augmented) 0.665 0.725 0.701
Table 1. Comparison of F1 score, precision and recall achieved on the different label
sets with a customized RetinaNet[7] approach.
and differences may lead to notable variation in performance. In this case the
model trained and tested on the alternative dataset yielded an higher F1 score
of 18.6 percentage points compared to the same model architecture trained and
tested on the original label set. The present results indicate that comparing
model performance between two different datasets should be done with caution.
The alternative datasets contains 28.80% more mitotic figure labels in the
training set. Some of these additional mitotic figures have a relatively low model
score, which could question the unambiguous nature of the labels regardless
of the overall higher F1 score. However, the increased model scores for the al-
gorithms trained on the alternative data, in comparison to the original data,
indicates a overall higher consistency. Regardless, both datasets include numer-
ous labels with low model score, which could potentially be explained by the high
morphological variability of mitotic figures and availability of very few patches of
some morphological variants for training. Large-scale datasets with even higher
numbers of mitotic figure labels might potentially overcome this limitation. Ad-
ditionally, different degrees of inconsistency have been described between pathol-
ogists [8,10,14] and pathologists-defined labels represent a somewhat noisy ref-
erence standard regardless agreement or consensus by several pathologists.
Besides the difficulties in the classification of mitotic figures, differences of
expert-defined labels may arise from lack of identifying rare events [15]. The
higher number of mitotic figure labels with presumably high label consistency
in the alternative datasets (see above), suggests that fewer mitotic figures were
overlooked. The labeling method of the alternative dataset basically follows the
paradigm of Viola and Jones [16], of having an initially highly sensitive detec-
tion, followed by a secondary classification with high specificity achieved through
dual expert consensus. High sensitivity in detecting potential mitotic figure la-
bels was achieved by repeated manual screening of the images and an additional
algorithmic augmentation. As the algorithmic detection of missed objects may
potentially introduce a confirmation bias, image patches were reviewed by two
pathologists independently. Final agreement on mitotic figures was only obtained
for 2.4% of the augmented cells, illustrating the desired high sensitivity / low
specificity of this approach for algorithmic mitotic figure detection. Thereby iden-
tification of presumably almost all mitotic figures (high number of true positives
and low number of false negatives) was ensured. Of note, adding this relatively
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low number of labels to the ground truth had a notable effect on performance
of up to 1.6 percentage points, consistent with previous findings [5].
Algorithmic approaches for dataset development have become more popu-
lar in recent years due to increasing demand on datasets that are difficult to
accomplish with solely manual approaches. As described above, algorithmically
supported identification of missed candidates may improve dataset quality and
requires algorithms with high sensitivity [5]. In contrast, enlargement of datasets
(higher quantity) may be facilitated through algorithmic detections with high
specificity in order to ensured that mainly true positives and only few false
positive labels are generated. This approach can be used for the creation of
datasets with reduced expenditure of expert labor (crowd sourcing [2] or expert-
algorithm-collaboration [9]), or fully automated generation of additional data
without pathologists-defined labels (pseudo-labels) [1]. Tellez et al. [12] recently
investigated another approach, that used an specific staining for mitotic figures
(immunohistochemistry with antibodies against phosphohistone H3) with com-
puterized detection of reference labels and subsequent registration to images of
the same tissue section with standard, non-specific hematoxylin and eosin stain.
Besides requiring minimal manual annotation effort, this methods may eliminate
expert-related inconsistency and inaccuracy.
In conclusion, this study shows considerable variability in pathologists-defined
labels. A subsequent effect was evident on training the models (variation of model
scores) and performance testing (variation of F1 score). This needs to be consid-
ered when robustness of algorithms or reproducibility of developed deep learning
methods are to be tested on independent ground truth datasets with different la-
beling methods. Therefore, scores should be interpreted in relation to reference
results on that specific datset. Further studies on reduction of expert-related
inconsistency and inaccuracy are encouraged.
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